
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1937381/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut, 2015, 64, 1680-1704.	12.1	518
2	Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology, 2009, 50, 825-833.	7.3	235
3	The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric varices: clinical and haemodynamic correlations. Gut, 2002, 51, 270-274.	12.1	192
4	Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut, 2020, 69, 1173-1192.	12.1	182
5	Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut, 2015, 64, 1111-1119.	12.1	168
6	Bleeding ectopic varices in cirrhosis: the role of transjugular intrahepatic portosystemic stent shunts. Alimentary Pharmacology and Therapeutics, 2008, 28, 294-303.	3.7	124
7	Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. Journal of Hepatology, 2014, 60, 1249-1258.	3.7	113
8	Endoscopic use of human thrombin in bleeding gastric varices. American Journal of Gastroenterology, 2002, 97, 1381-1385.	0.4	112
9	Good clinical outcomes following transjugular intrahepatic portosystemic stentâ€ s hunts in Budd–Chiari syndrome. Alimentary Pharmacology and Therapeutics, 2014, 39, 864-872.	3.7	92
10	Ten years??? follow-up of 472 patients following transjugular intrahepatic portosystemic stent-shunt insertion at a single centre. European Journal of Gastroenterology and Hepatology, 2004, 16, 9-18.	1.6	90
11	Portal vein thrombosis in cirrhosis: Controversies and latest developments. World Journal of Gastroenterology, 2015, 21, 6769-6784.	3.3	83
12	Improved clinical outcome with transjugular intrahepatic portosystemic stent-shunt utilizing polytetrafluoroethylene-covered stents. European Journal of Gastroenterology and Hepatology, 2006, 18, 225-232.	1.6	76
13	Haemodynamic effects of acute and chronic administration of lowâ€dose carvedilol, a vasodilating βâ€blocker, in patients with cirrhosis and portal hypertension. Alimentary Pharmacology and Therapeutics, 2002, 16, 373-380.	3.7	72
14	Increased Whole-Body and Sustained Liver Cortisol Regeneration by 11β-Hydroxysteroid Dehydrogenase Type 1 in Obese Men With Type 2 Diabetes Provides a Target for Enzyme Inhibition. Diabetes, 2011, 60, 720-725.	0.6	59
15	Review article: recent advances in the management of bleeding gastric varices. Alimentary Pharmacology and Therapeutics, 2006, 24, 1-17.	3.7	57
16	Recent advances in the management of variceal bleeding. Gastroenterology Report, 2017, 5, 113-126.	1.3	57
17	Transjugular intrahepatic portosystemic stent shunt (TIPSS) modification in the management of post-TIPSS refractory hepatic encephalopathy. Gut, 2006, 55, 1617-1623.	12.1	56
18	Variceal band ligation versus beta-blockers for primary prevention of variceal bleeding: a meta-analysis. European Journal of Gastroenterology and Hepatology, 2007, 19, 835-845.	1.6	46

#	Article	IF	CITATIONS
19	Betaâ€blockers in portal hypertension: new developments and controversies. Liver International, 2014, 34, 655-667.	3.9	45
20	Longâ€ŧerm outcomes following percutaneous hepatic vein recanalization for Budd–Chiari syndrome. Liver International, 2017, 37, 111-120.	3.9	45
21	The management of acute variceal bleeding. Alimentary Pharmacology and Therapeutics, 2003, 18, 253-262.	3.7	37
22	The role of carvedilol in the management of portal hypertension. European Journal of Gastroenterology and Hepatology, 2010, 22, 905-911.	1.6	37
23	An update on the diagnosis and management of Budd–Chiari syndrome. Expert Review of Gastroenterology and Hepatology, 2012, 6, 731-744.	3.0	35
24	Review article: a multidisciplinary approach to the diagnosis and management of Budd hiari syndrome. Alimentary Pharmacology and Therapeutics, 2019, 49, 840-863.	3.7	33
25	Pregnancy in idiopathic non-cirrhotic portal hypertension: A multicentric study on maternal and fetal management and outcome. Journal of Hepatology, 2018, 69, 1242-1249.	3.7	26
26	Outcomes of pregnancy in patients with known Budd-Chiari syndrome. World Journal of Hepatology, 2017, 9, 945.	2.0	21
27	A drug therapy for the prevention of variceal haemorrhage. Alimentary Pharmacology and Therapeutics, 2001, 15, 291-310.	3.7	20
28	Transjugular intrahepatic portosystemic stent-shunt in the management of gastric and ectopic varices. European Journal of Gastroenterology and Hepatology, 2006, 18, 1155-1160.	1.6	20
29	Transjugular intrahepatic portosystemic stent-shunt: technical factors and new developments. European Journal of Gastroenterology and Hepatology, 2006, 18, 1127-1133.	1.6	17
30	Embolization of Bleeding Stomal Varices by Direct Percutaneous Approach. CardioVascular and Interventional Radiology, 2011, 34, 210-213.	2.0	17
31	Retransplantation in Late Hepatic Artery Thrombosis: Graft Access and Transplant Outcome. Transplantation Direct, 2017, 3, e186.	1.6	14
32	Diastolic dysfunction on echocardiography does not predict survival after transjugular intrahepatic portosystemic stentâ€shunt in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 797-806.	3.7	14
33	Study protocol for a randomised controlled trial of carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis (CALIBRE trial). BMJ Open Gastroenterology, 2019, 6, e000290.	2.7	13
34	Timing of transjugular intrahepatic portosystemic stent-shunt in Budd–Chiari syndrome: A UK hepatologist's perspective. Journal of Translational Internal Medicine, 2018, 6, 97-104.	2.5	9
35	Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding—Longâ€ŧerm followâ€up of a randomised control trial. Alimentary Pharmacology and Therapeutics, 2022, , .	3.7	8
36	Drugs used in therapy of portal hypertension. Clinical Liver Disease, 2012, 1, 136-138.	2.1	7

#	Article	IF	CITATIONS
37	Role of early transjugular intrahepatic portosystemic stent-shunt in acute variceal bleeding: An update of the evidence and future directions. World Journal of Gastroenterology, 2021, 27, 7612-7624.	3.3	6
38	A case–control study of transjugular intrahepatic portosystemic stent shunts for patients admitted to intensive care following variceal bleeding. European Journal of Gastroenterology and Hepatology, 2013, 25, 344-351.	1.6	5
39	Endoscopic diagnosis, grading and predictors of bleeding in esophageal and gastric varices. Techniques in Gastrointestinal Endoscopy, 2005, 7, 2-7.	0.3	4
40	Economic evaluation of covered stents for transjugular intrahepatic portosystemic stent shunt in patients with variceal bleeding and refractory ascites secondary to cirrhosis. BMJ Open Gastroenterology, 2021, 8, e000641.	2.7	4
41	Patient Selection for Transjugular Intrahepatic Portosystemic Stent Shunt (TIPSS) Insertion in Variceal Bleeding and Refractory Ascites. Current Hepatology Reports, 2017, 16, 241-249.	0.9	3
42	Editorial: optimal dose of carvedilol in portal hypertension…nearly there. Alimentary Pharmacology and Therapeutics, 2018, 47, 1328-1329.	3.7	3
43	Prophylactic embolization of large spontaneous portosystemic shunts with transjugular intrahepatic portosystemic shunt (TIPS): A panacea for postâ€TIPS hepatic encephalopathy?. Hepatology, 2022, 76, 551-553.	7.3	3
44	Overview of the methods and therapies for the primary prevention of variceal bleeding. Expert Review of Gastroenterology and Hepatology, 2010, 4, 399-407.	3.0	2
45	Erythrocytes from patients with myeloproliferative neoplasms and splanchnic venous thrombosis show greater expression of Lu/ <scp>BCAM</scp> . International Journal of Laboratory Hematology, 2018, 40, 473-477.	1.3	2
46	Reply to: â€~ã€~Splenic artery aneurysms, portal hypertension and pregnancy― Journal of Hepatology, 2019, 70, 1026-1027.	3.7	2
47	Editorial: early TIPSS in patients with cirrhosis and acute variceal bleeding—the plot thickens!. Alimentary Pharmacology and Therapeutics, 2020, 52, 551-554.	3.7	2
48	Exploring patients' perceptions and experiences of treatments for the prevention of variceal bleeding: a qualitative study. BMJ Open Gastroenterology, 2021, 8, e000684.	2.7	2
49	Gastric Wall Invasion Following Transjugular Intrahepatic Portosystemic Stent Shunt Insertion for Variceal Bleeding. Endoscopy, 2006, 38, 545-545.	1.8	1
50	Rescue from liver transplantation: TIPSS and thrombectomy successfully treat a case of acute Budd–Chiari syndrome complicated by portal vein thrombosis. BJR case Reports, 2017, 3, 20160059.	0.2	1
51	Echocardiography in patients with cirrhosis does not predict the clinical outcome after Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS). Journal of Hepatology, 2017, 66, S381.	3.7	1
52	Editorial: predicting hepatic encephalopathy after <scp>TIPSS</scp> —is multimodal cerebral <scp>MRI</scp> the answer?. Alimentary Pharmacology and Therapeutics, 2018, 48, 1019-1020.	3.7	1
53	Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasms. A Study Of The IWG-MRT In 475 Subjects. Blood, 2013, 122, 1582-1582.	1.4	1
54	Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects. Blood, 2014, 124, 3163-3163.	1.4	1

#	Article	IF	CITATIONS
55	Commentary: TIPSS for Budd–Chiari syndrome – authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 39, 1238-1238.	3.7	0
56	Editorial: complications of TIPSS – consolidation of a decade of experience. Alimentary Pharmacology and Therapeutics, 2017, 45, 179-180.	3.7	0
57	Small Intrahepatic Vein Budd-Chiari Syndrome Complicated by Fusobacterium nucleatum Peritonitis. ACG Case Reports Journal, 2019, 6, e00121.	0.4	Ο
58	Portal Hypertension: Varices. In Clinical Practice, 2017, , 41-56.	0.0	0
59	Secondary Prophylaxis of Gastric Variceal Rebleeding: And the Winner Is….?. Liver Transplantation, 2022, 28, 918-919.	2.4	0